News and Trends 14 Sep 2022
Pancreatic cancer study using dual-cell therapy yields positive results
Australian biotech company Noxopharm Limited has revealed encouraging new preclinical data from its long-term collaboration with UNSW Sydney. The results were reported this week at the American Association of Cancer Research (AACR) Special Conference on Pancreatic Cancer in Boston. The study involves Noxopharm’s novel preclinical drug, which attacks pancreatic cancer in a different and innovative […]